Polyunsaturated Fatty Acids in Patients With NAFLD.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months. At the beginning and at the end of the study basic clinical and anthropometric data, as well as parameters of liver steatosis and fibrosis will be tested.
Epistemonikos ID: e578e66319342eba4e6390f23f48be5eaa83b21d
First added on: May 12, 2024